retatrutide ly3437943 glp-1 gip glucagon receptor agonist LY3437943, a novel triple GIP, GLP-1, and in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial retatrutide ly3437943 triple agonist glp-1
Pay in 4 interest-free payments of $6.21 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20

























